Nature Communications Study by Amelia Haj and Colleagues Identifies Factor XII as a Safer Target for Anticoagulation
Broad Institute of MIT and Harvard shared on LinkedIn:
”Patients diagnosed with life-threatening blood clots known as venous thromboembolisms (VTEs) are treated with anticoagulants, but these drugs increase their risk of bleeding.
In Nature Communications, Amelia Haj, Patrick Ellinor, Pavan Bendapudi, and collaborators make a genetic case for developing therapies targeting coagulation factor XII, a promising and potentially safer antithrombotic drug target.
They used UK Biobank and All of Us data to show that people who have lost one copy of the F12 gene have lower VTE risk without an increased risk of bleeding.
Their study suggests that inhibiting factor XII would likely be a safe and effective approach for anticoagulation.”
Read the full article in Nature Communications.
Article: Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis
Authors: Amelia K. Haj, David S. Paul, Sean J. Jurgens, Harish Eswaran, Lu-Chen Weng, Justine Ryu, Alfonso Rodriguez Espada, Sharjeel Chaudhry, Louis M. Feingold, Kristen Burke, Satoshi Koyama, Xin Wang, Joyce Francis, Seung Hoan Choi, Nigel Mackman, Wolfgang Bergmeier, Alex Burgin, Joel T. Rämö, Patrick T. Ellinor, Steven P. Grover , Pavan K. Bendapudi

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 12, 2026, 15:40Anne-Claire Duchez: Join Us at ISTH 2026 to Discover Our Latest Research and Meet the Team
-
Jul 12, 2026, 12:30Reduced-Dose DOACs in GI Malignancies: Toward Personalized Anticoagulation
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research